NASDAQ:TBPH

Theravance Biopharma (TBPH) Stock Forecast, Price & News

$8.63

+0.25 (+2.98%)

(As of 09/29/2023 ET)

Compare

Today's Range: $8.25
▼
$8.67
50-Day Range: $8.38
▼
$10.20
52-Week Range: $8.25
▼
$12.03

Volume: 474,661 shs
Average Volume: 546,864 shs
Market Capitalization: $455.75 million

P/E Ratio: 0.76
Dividend Yield: N/A
Price Target: $17.00

Theravance Biopharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 97.0% Upside
$17.00 Price Target
Short Interest: Bearish
20.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$87,705 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.06) to ($0.54) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

344th out of 970 stocks

Pharmaceutical Preparations Industry

143rd out of 449 stocks

3.5

Analyst's Opinion

Consensus Rating
Theravance Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.00, Theravance Biopharma has a forecasted upside of 97.0% from its current price of $8.63.
Amount of Analyst Coverage
Theravance Biopharma has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
20.25% of the float of Theravance Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Theravance Biopharma has a short interest ratio ("days to cover") of 19.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Theravance Biopharma has recently increased by 0.78%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Theravance Biopharma does not currently pay a dividend.
Dividend Growth
Theravance Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TBPH.

3.8

News and Social Media Coverage

News Sentiment
Theravance Biopharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Theravance Biopharma this week, compared to 1 article on an average week.
Search Interest
3 people have searched for TBPH on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
1 people have added Theravance Biopharma to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $87,705.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Theravance Biopharma is held by insiders.
Percentage Held by Institutions
99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Theravance Biopharma are expected to grow in the coming year, from ($1.06) to ($0.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Theravance Biopharma is 0.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.50.
Price to Earnings Ratio vs. Sector
The P/E ratio of Theravance Biopharma is 0.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 107.49.
Price to Book Value per Share Ratio
Theravance Biopharma has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

TBPH Price History

30 days | 90 days | 365 days | Advanced Chart

TBPH Stock News Headlines

September 9, 2023 | msn.com

Theravance: Positive Findings Boost Ampreloxetine Development

September 8, 2023 | msn.com

Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold

September 30, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

August 28, 2023 | finance.yahoo.com

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

August 9, 2023 | finance.yahoo.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2023 Earnings Call Transcript

August 8, 2023 | msn.com

HC Wainwright & Co. Reiterates Theravance Biopharma (TBPH) Buy Recommendation

August 8, 2023 | finance.yahoo.com

Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

August 8, 2023 | seekingalpha.com

Theravance Biopharma GAAP EPS of -$0.28 misses by $0.07, revenue of $13.75M misses by $1.67M

September 30, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

August 7, 2023 | seekingalpha.com

Theravance Biopharma, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 1, 2023 | msn.com

Top Stocks for August 2023

July 28, 2023 | fool.com

Theravance Biopharma (NASDAQ: TBPH)

July 24, 2023 | finance.yahoo.com

Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023

June 7, 2023 | finance.yahoo.com

Why Is Theravance Bio (TBPH) Down 3.8% Since Last Earnings Report?

May 10, 2023 | finance.yahoo.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2023 Earnings Call Transcript

May 10, 2023 | finance.yahoo.com

Theravance Biopharma First Quarter 2023 Earnings: US$0.35 loss per share (vs US$0.34 loss in 1Q 2022)

May 9, 2023 | finance.yahoo.com

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

May 9, 2023 | finance.yahoo.com

Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates

May 9, 2023 | seekingalpha.com

Theravance Biopharma, Inc. 2023 Q1 - Results - Earnings Call Presentation

May 8, 2023 | markets.businessinsider.com

Theravance Biopharma Inc. Q1 Loss misses estimates

May 8, 2023 | finance.yahoo.com

Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 7, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Theravance Biopharma's earnings

May 5, 2023 | seekingalpha.com

Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return

April 24, 2023 | finance.yahoo.com

Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023

April 17, 2023 | finance.yahoo.com

Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Share Price Not Quite Adding Up

April 13, 2023 | bizjournals.com

Companies make some concessions to activist investors. Will it work?

April 12, 2023 | msn.com

Theravance Biopharma ticks higher amid appointment of new director

See More Headlines

Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Company Calendar

Last Earnings: 8/07/2023
Today: 9/30/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TBPH
Previous Symbol: NASDAQ:TBPHV
CUSIP: N/A
CIK: 1583107
Web: www.theravance.com
Phone: (650) 808-6000
Fax: N/A
Employees: 359
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.00
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +97.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $11.36
Trailing P/E Ratio: 0.76
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $872.13 million
Net Margins: 1,694.17%
Pretax Margin: -130.60%
Return on Equity: -16.88%
Return on Assets: -11.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.82
Quick Ratio: 7.82

Sales & Book Value

Annual Sales: $51.35 million
Price / Sales: 8.88
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.56 per share
Price / Book: 1.32

Miscellaneous

Outstanding Shares: 52,810,000
Free Float: 50,014,000
Market Cap: $455.75 million
Optionable: Optionable
Beta: 0.43

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Rick E. Winningham
Chairman & Chief Executive Officer

Andrew Asa Hindman
Chief Financial Officer & Senior Vice President

Vijay Sabesan
Senior Vice President-Technical Operations

Philip D. Worboys
Senior VP-Research & Translational Science

Bradford J. Shafer
Secretary, Executive VP & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TBPH Stock - Frequently Asked Questions

Should I buy or sell Theravance Biopharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TBPH shares.
View TBPH analyst ratings or view top-rated stocks.
What is Theravance Biopharma's stock price forecast for 2023?: 2 Wall Street analysts have issued 12 month target prices for Theravance Biopharma's shares. Their TBPH share price forecasts range from $14.00 to $20.00. On average, they anticipate the company's share price to reach $17.00 in the next year. This suggests a possible upside of 97.0% from the stock's current price.
View analysts price targets for TBPH or view top-rated stocks among Wall Street analysts.
How have TBPH shares performed in 2023?: Theravance Biopharma's stock was trading at $11.22 on January 1st, 2023. Since then, TBPH stock has decreased by 23.1% and is now trading at $8.63.
View the best growth stocks for 2023 here.
When is Theravance Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our TBPH earnings forecast.
How were Theravance Biopharma's earnings last quarter?: Theravance Biopharma, Inc. (NASDAQ:TBPH) announced its quarterly earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.06. The biopharmaceutical company earned $13.75 million during the quarter, compared to analyst estimates of $15.24 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 16.88% and a net margin of 1,694.17%.
What ETFs hold Theravance Biopharma's stock?: ETFs with the largest weight of Theravance Biopharma (NASDAQ:TBPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What other stocks do shareholders of Theravance Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).
What is Theravance Biopharma's stock symbol?: Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."
How do I buy shares of Theravance Biopharma?: Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Theravance Biopharma's stock price today?: One share of TBPH stock can currently be purchased for approximately $8.63.
How much money does Theravance Biopharma make?: Theravance Biopharma (NASDAQ:TBPH) has a market capitalization of $455.75 million and generates $51.35 million in revenue each year. The biopharmaceutical company earns $872.13 million in net income (profit) each year or $11.36 on an earnings per share basis.
How many employees does Theravance Biopharma have?: The company employs 359 workers across the globe.
How can I contact Theravance Biopharma?: Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The official website for the company is www.theravance.com. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at investor.relations@theravance.com.

This page (NASDAQ:TBPH) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial